Related Experiment Video
Updated: Mar 28, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
TAS-102 an Emerging Oral Fluoropyrimidine
Jiezhong Chen1, Mei Han2, Muhammad Wasif Saif3
1School of Biomedical Sciences, University of Queensland, St. Lucia, Australia.
TAS-102, a novel drug combining trifluridine and tipiracil, shows promise for colon cancer treatment. Further research into combination therapies may enhance its efficacy against this deadly disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Colon cancer has high mortality, with limited efficacy of standard 5-fluorouracil (5-FU) chemotherapy (10-15% response rate).
- Existing strategies to improve 5-FU efficacy include DPD inhibition, capecitabine (a 5-FU prodrug), and folate supplementation.
Purpose of the Study:
- To review the progress of TAS-102, a novel anti-folate drug for colon cancer.
- To explore potential strategies for enhancing TAS-102 efficacy.
Main Methods:
- Review of pre-clinical data and clinical trial results for TAS-102.
- Analysis of TAS-102's mechanism of action, involving trifluridine (TFD) and tipiracil hydrochloride (TPI).
Main Results:
- TAS-102 combines trifluridine (TFD), a 5-FU analogue, with tipiracil hydrochloride (TPI).
- Tipiracil hydrochloride inhibits thymidine phosphorylase, increasing TFD bioavailability and efficacy.
Conclusions:
- TAS-102 represents a new therapeutic option for colon cancer.
- Combination therapy with targeted agents or immunotherapy may further improve TAS-102 outcomes.
More Related Videos
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
10:24A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
Published on: January 27, 2026
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Treatment Resistent Cancers
Oral Hypoglycemic Agents: Sulfonylureas
Treatment Resistant Cancers
Oral Drug Delivery Systems: Introduction
Subviral Agents